Some Adverse Events For Generics Still Should Not Be Submitted Through eCTD Portal, US FDA Says
Executive Summary
Implementation of eCTD regulations for commercial INDs did not change system for submitting premarket bioavailability/bioequivalence study reports intended to support ANDA approval, agency clarifies.